Personalized dosing of Immune-Suppressing drug may improve stem cell transplant outcomes
NCT ID NCT05166967
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tested whether giving an individualized dose of antithymocyte globulin (ATG) based on a patient's own drug levels works better than a standard fixed dose. The goal was to reduce graft-versus-host disease (a serious immune reaction) and virus reactivation after a half-matched stem cell transplant. The study enrolled 204 patients and compared survival without these complications between the two dosing groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- antithymocyte globulin (ATG)
- What this could lead to
- If successful, this could show that tailoring ATG doses reduces serious complications like graft-versus-host disease and viral infections after stem cell transplants.
- What could go wrong
- This is a completed phase 3 trial, but results are not yet published. The approach may not significantly improve outcomes over standard fixed dosing, and risks like infection or graft failure remain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can a new tracer light up cancer growth?
- Could a walk a day keep brain fog away after a stem cell transplant?
- Could End-of-Life care for blood cancer patients be done at home?